Corvidia Therapeutics
Biotechnology company that developed ziltivekimab, an anti-IL-6 antibody for cardiovascular and kidney diseases. Acquired by Novo Nordisk in 2020 for up to $2.1 billion.
Website
https://www.corvidiatx.comLocation
Waltham, Massachusetts, USA
Founded
2015
Investors
2
Categories
biotech, cardiovascular, therapeutics, inflammation, kidney-disease
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Sofinnova Partners | Paris, France | biotech-focused | seedseries-a+3 | 23 |
| Apple Tree Partners | New York, USA | biotech-focused | series-aseries-b+2 | 23 |